TY - JOUR T1 - Childhood-onset severe hypereosinophilic asthma: efficacy of benralizumab JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00339-2020 SP - 00339-2020 AU - J. Just AU - M. Bourgoin AU - F. Amat AU - N. Cottel AU - N. Lambert AU - S. Wanin Y1 - 2020/01/01 UR - http://openres.ersjournals.com/content/early/2020/09/24/23120541.00339-2020.abstract N2 - Hypereosinophilic syndrome (HES) is a group of rare chronic disorders that are defined by an absolute blood eosinophil count (BEC) of at least 1.500×109 cells·L−1 on at least two occasions [1] with absence of secondary causes of eosinophilia (including parasitic infections, malignancy as myeloproliferative variants) and end-organ eosinophilic infiltration with associated damage [2]. In 2006, a working group modified the definition of HES to include other previously distinct disease entities associated with eosinophilia, such as eosinophilic granulomatosis with polyangiitis (EGPA, formerly known as Churg-Strauss syndrome) and chronic eosinophilic pneumonia [3]. EGPA typically occurs in middle-age adults with asthma and childhood-onset is rare with a prevalence of 10–13 patients per million people [4, 5]. We report here a series of six children with childhood-onset asthma with oral corticosteroid (OCS) dependence associated with hypereosinophilic asthma with a long-term follow-up and the marked efficacy of benralizumab. The study was declared to the French Data Protection Authority (CNIL) according to the reference methodology MR004. All the included patients or their parents received an information note and could have opposed the use of their personal data, but no refusals were received.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of interest: Dr. JUST reports grants and personal fees from Novartis, grants from ALK- Abello, personal fees from Stallergenes, personal fees from Astra-Zeneca, personal fees from Thermofischer, outside the submitted work;.Conflict of interest: Dr. Bourgoin reports grants from Stallergène, grants from ALK -abello, personal fees from Novartis, outside the submitted work;.Conflict of interest: Dr. Amat has nothing to disclose.Conflict of interest: Dr. Cottel has nothing to disclose.Conflict of interest: Dr. LAMBERT has nothing to disclose.Conflict of interest: Dr. Wanin has nothing to disclose. ER -